TY - JOUR T1 - Osimertinib as a second-line treatment for EGFR-mutated non-small cell lung cancer: the experience of a Pulmonology department JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2020.1693 VL - 56 IS - suppl 64 SP - 1693 AU - Daniela Dantas Barreto Rodrigues AU - Catarina Lacerda AU - Filipa Aguiar AU - Maria João Araújo AU - Diana Pimenta AU - Lurdes Ferreira Y1 - 2020/09/07 UR - http://erj.ersjournals.com/content/56/suppl_64/1693.abstract N2 - Introduction: The third-generation tyrosine kinase inhibitor (TKI) osimertinib is recommended as first-line therapy for advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, as it has shown to improve overall survival when compared to first-generation TKI. However, upon disease progression no other targeted therapies are yet available, and chemotherapy is the standard option.Objectives: We aim to assess the number of patients treated with first and second-generation TKI who went on to receive a second-line therapy including osimertinib.Methods: Retrospective analysis of NSCLC patients with EGFR mutations treated with first and second-generation TKI between 2017 and 2019. Descriptive data analysis was performed.Results: We identified 42 patients, of which 66.7% were female and mean age was 72.8±11 years. Erlotinib was the first-line TKI in 59.5% of the cases. Disease progression was seen in 52.4% of the subjects, while 23.8% died without documented progression and 23.8% showed no disease progression. The mean progression-free survival on TKI was 21.6±14 months. T790M resistance mutation was tested in 33.3% of the subjects, with a positive result seen in 50%. In total, only 19% of the patients were given a second-line therapy, of which 75% received osimertinib. Overall, only 14.3% received osimertinib. In 46.7% of the cases, patients died without receiving a subsequent treatment.Conclusion: Our experience showed that most patients do not go on to receive a second-line therapy, mainly due to death. Given that osimertinib has better outcomes in overall survival it should be used as first-line therapy.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 1693.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -